DOI : 10.1055/s-00000034

Klinische Pädiatrie

Issue 06 · Volume 224 · November 2012 DOI: 10.1055/s-002-23937


21th Annual Meeting – of the Working Group “Experimental Neuro-Oncology”
Johannes Wesling Klinikum Minden, 27th–28th April 2012

Wissenschaftliche Leitung: Prof. Dr. B. Erdlenbruch
Abstracts (HTML) List of Authors
A3
Bangert, A; Cristofanon, S; Eckhardt, I; Ahangarian Abhari, B; Kolodziej, S; Häcker, S; Hari Krishna Vellanki, S; Lausen, J; Debatin, KM; Fulda, S: Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc- mediated downregulation of cFLIP
Editorial
Erdlenbruch, B: Editorial
A1
Grube, S; Walter, J; Dünisch, P; Freitag, D; Kalff, R; Ewald, C: Establishing short term cultures from human brain tumours and metastases to analyze reduction of cell proliferation by antitumoural drugs
A2
Borchardt, C; Unland, R; Clemens, D; Kerl, K; Hempel, G; Frühwald, MC: Effects of histone methyltransferase inhibitor 3-Deazaneoplanocin (DZNep) on rhabdoid tumor cell lines
A4
Unland, R; Schlosser, S; Farwick, N; Plagemann, T; Richter, G; Jürgens, H; Frühwald, MC: Epigenetic silencing of the Dopamine Receptor D4 in medulloblastoma
A5
Cin, H; Gronych, J; Korshunov, A; Jones, DTW; Milford, D; Milde, T; Heiland, S; Lichter, P; Witt, O; Pfister, SM: Investigation of BRAF fusion genes as a therapeutic target in pilocytic astrocytoma
A6
Koks, C; Alkassar, M; De Vleeschouwer, S; Graf, N; Van Gool, S: Combining DC-mediated immunotherapy with oncolytic virotherapy in the treatment of HGG
A7
Gielen, GH; zur Mühlen, A; Kramm, C; Pietsch, T: Identification of p53 accumulation, EGFR gain and PDGFRα gain/amplification as adverse prognostic factors in pediatric high grade gliomas – evaluation of 48 cases of the German HIT-HGG trial
A8
Knizhnik, A; Quiros, S; Barckhausen, C; Roos, WP; Kaina, B: DNA Damaging Drugs in the Treatment of Glioblastoma: HR, Apoptosis, Autophagy and Senescence
A9
Lacroix, J; Josupeit, R; Kern, S; Herold-Mende, C; Schlund, F; Witt, H; Milde, T; Leuchs, B; Pfister, SM; Witt, O; Schlehofer, JR; Rommelaere, J: Parvovirus H-1 (H-1PV) exerts oncolytic effects in cell culture models of human brain tumor-initiating cells
A10
Milde, T; Zucknick, M; Kool, M; Korshunov, A; Witt, H; Jugold, M; Deimling, A von; Kulozik, AE; Benner, A; Pfister, S; Witt, O: The Pediatric Brain Tumor Preclinical Testing Program: an update on the current status
A11
Milde, T; Hielscher, T; Witt, H; Kool, M; Mack, SC; Deubzer, HE; Oehme, I; Lodrini, M; Benner, A; Taylor, MD; Deimling, A von; Kulozik, AE; Pfister, SM; Witt, O; Korshunov, A: Nestin protein expression is an independent prognostic marker in ependymoma and discriminates WHO II ependymoma with poor outcome
A12
Patties, I; Kortmann, RD; Glasow, A: Combinatorial effects of Resveratrol, 5-aza-2'deoxycytidin, and irradiation on clonogenic survival and stem cell population in human Medulloblastoma cell lines
A13
Hambsch, P; Kortmann, RD; Schastak, S; Glasow, A: Photodynamic treatment with Tetrahydroporphyrin Tetratosylat induces programmed cell death in human glioblastoma cell lines
A14
Schubert, J; Mullins, C; Piek, J; Classen, CF: Sensitivity of primary Glioblastoma cell lines towards Cilengitide alone and in combination with Temozolomide
A15
Tzaridis, TD; Witt, H; Milde, T; Bender, S; Pfaff, E; Jones, DTW; Kulozik, AE; Lichter, P; Korshunov, A; Witt, O; Pfister, SM: Actinomycin-D treatment of high-risk ependymomas re-establishes the apoptotic function of p53
A16
Van Gool, S; Pauwels, F; De Vleeschouwer, S: Immunotherapy for high grade glioma: current clinical practice for patients with (relapsed) GBM